Werner Baumann - Bayer AG Executive

BAYZF Stock  USD 25.96  0.05  0.19%   

Executive

Mr. Werner Baumann has served as Chairman of the Management Board and Chief Executive Officer of Bayer Aktiengesellschaft since May 1, 2016. Previously he served as Member of the Management Board, Strategy and Portfolio Management, EuropeMiddle EastAfrica Region at Bayer AG from January 1, 2016 till April 30, 2016. After studying economics at RWTH Aachen Universitaet and the University of Cologne, he joined Bayer in 1988. His first duties were in the Corporationrationrate Finance Department in Leverkusen. In 1991 he transferred to Bayer Hispania Comercial in Barcelona, Spain, to take up a position as controller, becoming assistant to the managing director in 1995. A year later, Baumann moved to Bayer Corporation in Tarrytown, New York, latterly heading up the global Business Planning Administration organization of the Diagnostics Business Group. In July 2002, Baumann returned to Germany to become a member of the Executive Committee and Head of Central Administration Organization at Bayer HealthCare. In October 2003 he was appointed a member of the Board of Management of the newly formed subgroup Bayer HealthCare AG, also serving as the company Labor Director. As a member of the Board of Management and Labor Director of Bayer Schering Pharma AG, Berlin, Germany, from 2006 through September 2009, he actively participated in this company integration into the subgroup. Prior to October 1, 2014, he served as Bayer AGs Chief Financial Officer . since 2016.
Age 61
Tenure 9 years
Phone49 214 30 1
Webhttps://www.bayer.com

Bayer AG Management Efficiency

The company has return on total asset (ROA) of 0.0576 % which means that it generated a profit of $0.0576 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.13 %, meaning that it generated $0.13 on every $100 dollars invested by stockholders. Bayer AG's management efficiency ratios could be used to measure how well Bayer AG manages its routine affairs as well as how well it operates its assets and liabilities.
Bayer AG has accumulated 35.55 B in total debt with debt to equity ratio (D/E) of 1.17, which is about average as compared to similar companies. Bayer AG has a current ratio of 1.16, suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due. Debt can assist Bayer AG until it has trouble settling it off, either with new capital or with free cash flow. So, Bayer AG's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bayer AG sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bayer to invest in growth at high rates of return. When we think about Bayer AG's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Elena LokisGetty Realty
N/A
Lucas ChangUnited Microelectronics
70
Edward FergusonIAC Inc
N/A
Wenchi TingUnited Microelectronics
N/A
M HsuUnited Microelectronics
N/A
Ming HsuUnited Microelectronics
N/A
James FlynnAviat Networks
N/A
Shane DorcheusAlbertsons Companies
N/A
Steven LiuUnited Microelectronics
N/A
Thomas MoriartyAlbertsons Companies
61
YS ShenUnited Microelectronics
N/A
Francia HsuUnited Microelectronics
N/A
John WeaverIPG Photonics
N/A
Joshua KoplikIAC Inc
N/A
Gary CrokeAviat Networks
53
Robert LarsonAlbertsons Companies
54
Zhenlun ZhangUnited Microelectronics
N/A
Muliang LiaoUnited Microelectronics
N/A
Jason AndersonTitan Machinery
N/A
Lauren GeerIAC Inc
N/A
Steve JDTitan Machinery
N/A
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany. Bayer Ag is traded on OTC Exchange in the United States. Bayer AG [BAYZF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Bayer AG Leadership Team

Elected by the shareholders, the Bayer AG's board of directors comprises two types of representatives: Bayer AG inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bayer. The board's role is to monitor Bayer AG's management team and ensure that shareholders' interests are well served. Bayer AG's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bayer AG's outside directors are responsible for providing unbiased perspectives on the board's policies.
Sarena Lin, Labor Officer
Oliver Maier, Head Relations
Gabriel Harnier, Patents Law
Heiko Schipper, Member of the Management Board, Head of the Consumer Health Division
Rodrigo Santos, Member Division
Michael Preuss, Gov Communications
Stefan Oelrich, Member of the Management Board, Head of the Pharmaceuticals Division
Wolfgang Nickl, CFO, Member of the Management Board
BerndPeter Bier, Head Taxes
Werner Baumann, Chief Strategy and Portfolio Officer and Member of Management Board

Bayer Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bayer AG a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Other Information on Investing in Bayer Pink Sheet

Bayer AG financial ratios help investors to determine whether Bayer Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bayer with respect to the benefits of owning Bayer AG security.